Plain-English translation of NCT03033576 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial examined whether combining two immunotherapy drugs— and —worked better than alone for people with advanced melanoma that had stopped responding to an earlier immunotherapy. Both treatment approaches were tested in patients whose cancer had progressed despite prior anti-PD-1 or anti-PD-L1 therapy. The trial aimed to see which approach helped patients live longer without their cancer getting worse.
When melanoma stops responding to standard immunotherapy drugs, patients need new treatment options. This trial investigated whether using two complementary immunotherapy medications together might help people whose cancer had become resistant to single-agent immunotherapy.
Participants were randomly assigned to receive either alone or the combination of plus . Both groups received intravenous infusions on a regular schedule over several months—either 4 cycles of treatment every 3 weeks, or 4 cycles every 3 weeks followed by ongoing single-drug maintenance therapy every 4 weeks. Participants attended clinic visits for infusions, imaging scans to monitor their cancer, and blood tests to check for side effects throughout the trial.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
United States